Asia Pacific Antibody Drug Conjugates Market
市场规模（十亿美元）
CAGR :
% 
USD
2.06 Billion
USD
7.10 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 2.06 Billion |
 Market Size (Forecast Year) |
USD 7.10 Billion |
 CAGR |
% |
| Major Markets Players |
|
亞太抗體藥物偶聯物 (ADC) 市場細分、按產品（Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 等）、抗原成分（HER2 受體、Trop-2、CD79in、CD30in 4、CD22、CD19、CD33、組織因子等）、抗體成分（第三代 ADC、第二代 ADC、第四代 ADC 和第一代 ADC）、連接子成分（可裂解連接子和不可裂解連接子）、細胞毒性有效載荷或彈頭成分（DNA損傷劑和微管破壞劑）、連接子技術（勝肽連接子、硫醚連接子、腙連接子和二硫鍵連接子）、偶聯技術（位點特異性結合和化學結合）、適應症（乳腺癌、血癌（白血病、淋巴瘤）、肺癌、婦科癌症、胃腸道癌症、泌尿生殖系統癌症等）、最終用戶（醫院、專科診所2032 年）
亞太地區抗體藥物偶聯物（ADC）市場規模
- 2024 年亞太地區抗體藥物偶聯物 (ADC) 市場規模為20.6 億美元 ，預計 到 2032 年將達到 71 億美元，預測期內 複合年增長率為 16.70%。
- 市場成長主要得益於中國、日本和韓國等國家癌症負擔的增加、腫瘤學研究投入的增加以及標靶治療的普及
- 此外，精準醫療的日益普及，以及政府為促進生物製藥創新而出台的利多舉措，使得ADC成為癌症治療的首選方案。這些因素共同推動了對ADC療法的強勁需求，從而顯著推動了該地區市場的擴張。
亞太抗體藥物偶聯物（ADC）市場分析
- 抗體藥物偶聯物 (ADC) 結合了單株抗體的標靶能力和細胞毒性藥物的強效細胞殺傷作用，由於其療效增強、標靶遞送和全身毒性降低，正在成為亞太地區腫瘤治療領域的一類關鍵療法
- ADC 需求的成長主要源於癌症盛行率的上升、醫療基礎設施的改善以及中國和印度等新興經濟體獲得先進生物製藥的機會的增加
- 中國在亞太抗體藥物偶聯物 (ADC) 市場佔據主導地位，2024 年其收入份額最高，為 48.1%，這得益於監管審批的加速、廣泛的臨床研究活動，以及國內公司與專注於新型 ADC 管線的全球生物技術公司之間的戰略合作夥伴關係
- 預計日本將見證抗體藥物偶聯物 (ADC) 市場最快的成長，這得益於高昂的醫療支出、成熟的製藥業以及患者對標靶癌症治療意識的不斷提高
- 乳癌領域在亞太抗體藥物偶聯物 (ADC) 市場佔據主導地位，2024 年在亞太抗體藥物偶聯物 (ADC) 市場的份額為 40.2%，這歸因於乳癌發生率高、診斷率不斷提高，以及已有多種針對 HER2 陽性乳癌的核准 ADC 療法
報告範圍和亞太抗體藥物偶聯物（ADC）市場細分
|
屬性 |
亞太地區抗體藥物偶聯物（ADC）市場關鍵洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
亞太
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
亞太地區抗體藥物偶聯物（ADC）市場趨勢
“臨床試驗和本地生物技術合作激增”
- 亞太 ADC 市場的一個重要且加速的趨勢是區域特定臨床試驗的激增以及當地生物技術公司與全球製藥公司之間的策略合作，旨在加速新型 ADC 療法的開發和商業化
- 例如，2024 年，總部位於中國的百奧金製藥公司與一家美國生物技術公司達成了一項聯合開發協議，以推進針對 HER2 的 ADC 產品線，這體現了該地區不斷提升的研發能力和監管改革推動的國際合作模式的不斷發展
- 腫瘤藥物研發管線投資的不斷增加以及監管框架的完善（尤其是在中國和韓國），使得ADC等創新療法的審批速度加快，審批途徑簡化。這些進步正鼓勵本土和跨國公司擴大臨床試驗業務，並建立在地化生產設施。
- 此外，該地區各國政府，尤其是中國和日本，正積極資助癌症研究和精準醫療項目，為ADC創新創造有利環境。值得關注的措施包括中國「健康中國2030」規劃和日本「癌症防治促進法」的資金投入，這兩項法案都旨在透過先進療法改善腫瘤治療結果。
- 先進的連接技術與位點特異性偶聯技術的整合也在區域開發中日益受到關注，使ADC能夠實現更高的治療指數並改善安全性。這正在重塑治療標準，並將ADC定位為靶向癌症治療的一線選擇。
- 因此，亞太地區正成為一個有吸引力的 ADC 研究中心，得益於強大的科學專業知識、不斷增加的腫瘤學試驗患者群體以及支持快速創新和審批的有利監管環境
亞太地區抗體藥物偶聯物（ADC）市場動態
司機
“癌症負擔日益加重，標靶治療需求不斷增長”
- 亞太地區各種癌症發生率的上升，加上精準腫瘤學意識的不斷增強，是推動該地區對 ADC 需求的主要驅動力
- 例如，世界衛生組織估計，2024年亞洲將新增超過900萬例癌症病例，其中以乳癌、肺癌和胃癌最為常見。這一驚人的成長態勢正導致對創新治療方案的需求不斷增長，例如與傳統化療相比，特異性更高、毒性更低的ADC藥物。
- 此外，生物製劑價格的日益親民，以及中國和日本等主要市場的健保覆蓋率的不斷提升，也支持了ADC療法的廣泛普及。優惠的報銷政策和國家健保計畫也透過減輕病患的經濟負擔，鼓勵病患採用高成本療法。
- 該地區的生物製藥投資也在激增，Seagen 和第一三共等公司透過本地合作和擴大臨床計畫來拓展其 ADC 業務。這些策略性措施正在加快 ADC 的開發週期，並提高該地區 ADC 的可及性。
- 此外，區域 CRO 和 CDMO 能力的不斷增強，正在支援從早期研究到商業規模生產的端到端 ADC 開發，進一步增強本地市場準備度
克制/挑戰
“製造過程複雜且監管多變”
- 儘管具有成長潛力，但亞太地區的 ADC 市場仍面臨顯著挑戰，包括生產 ADC 的高製造複雜性和高成本，這限制了該地區部分地區的可及性和可擴展性
- ADC 需要精確的結合化學、高密閉性製造和嚴格的品質控制，所有這些都推高了生產成本。這些技術障礙可能會限制缺乏基礎設施或資金投資 ADC 開發和生產的小型生物技術公司進入市場。
- 此外，亞太地區各國監管不一致也為區域無縫商業化帶來了障礙。儘管中國和日本已簡化了生物製劑的審批流程，但其他國家仍面臨冗長的審批流程或缺乏明確的ADC特定指南。
- 這些障礙可能會延遲市場進入，並限制跨境合作，尤其是對於新進入者而言。此外，一些新興市場缺乏經驗豐富的勞動力和技術專長，這可能會進一步阻礙ADC的採用和創新。
- 透過協調監管框架、增加對生物製造能力的公私投資以及 ADC 生產培訓計劃來克服這些障礙，對於確保亞太地區的持續成長和公平獲取至關重要
亞太抗體藥物偶聯物（ADC）市場範圍
市場根據產品、抗原成分、抗體組成、連接體成分、細胞毒性有效載荷、連接體技術、結合技術、適應症、最終用戶和分銷管道進行細分。
- 按產品
根據產品類型，亞太地區抗體藥物偶聯物 (ADC) 市場細分為 Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 和其他。 Enhertu 細分市場在 2024 年佔據市場主導地位，佔據最大的市場收入份額，這得益於其在 HER2 陽性癌症中的廣泛臨床應用以及在日本、中國和韓國等亞太主要國家的強勁增長。 Enhertu 在多種實體瘤適應症中擁有穩健的療效數據和監管部門的批准，鞏固了其在區域 ADC 領域的領先地位。
預計Polivy領域將在2025年至2032年期間實現最快增長，這得益於其在治療瀰漫性大B細胞淋巴瘤(DLBCL)方面的日益普及以及被納入區域治療指南。羅氏的策略擴張以及腫瘤中心報銷覆蓋範圍的不斷擴大，將進一步支持其在該市場的快速成長。
- 依抗原成分
根據抗原成分，亞太地區抗體藥物偶聯物 (ADC) 市場細分為 HER2 受體、Trop-2、CD79B、CD30、Nectin 4、CD22、CD19、CD33、組織因子和其他。 HER2 受體細分市場在 2024 年佔據最大收入份額，這歸因於 HER2 陽性癌症的高盛行率以及針對該抗原的先進 ADC 的可用性，包括 Kadcyla 和 Enhertu。
預計 Trop-2 領域將在預測期內實現最快的成長率，這得益於 Trodelvy 的使用量不斷增加以及該地區對用於治療侵襲性乳腺癌和尿路上皮癌的 Trop-2 標靶藥物的臨床興趣日益濃厚。
- 按抗體成分
根據抗體的生成，亞太地區抗體藥物偶聯物 (ADC) 市場可分為第一代 ADC、第二代 ADC、第三代 ADC 和第四代 ADC。第二代 ADC 市場在 2024 年佔據主導地位，佔據最大份額，這得益於 Kadcyla 和 Adcetris 等 ADC 的臨床成功和商業化應用，這些 ADC 具有更高的穩定性和療效。
第三代 ADC 領域預計將在 2025 年至 2032 年間以最快的速度成長，這得益於區域開發商和全球製藥合作夥伴所採用的位點特異性結合技術進步和安全性改進。
- 按連結器組件
根據連接體成分，亞太地區抗體藥物偶聯物 (ADC) 市場細分為可裂解連接體和不可裂解連接體。可裂解連接體在 2024 年佔據了大部分市場收入份額，這得益於其能夠在腫瘤環境中選擇性釋放細胞毒性藥物，從而降低全身毒性並改善治療效果。
不可裂解連接體部分預計將在預測期內以最快的速度增長，特別是在血液系統惡性腫瘤中，其中細胞內降解機制即使沒有連接體裂解也能促進有效的藥物釋放。
- 依細胞毒性有效載荷或彈頭組件
根據細胞毒性有效載荷，亞太地區抗體藥物偶聯物 (ADC) 市場細分為 DNA 損傷劑和微管破壞劑。微管破壞劑細分市場在 2024 年佔據市場主導地位，這得益於其在 Kadcyla 和 Adcetris 等成熟 ADC 中的成功應用。這些藥物具有強大的抗腫瘤活性，並已在實體癌和血癌治療中顯示出良好的療效。
由於 DNA 損傷劑具有獨特的機制以及在下一代 ADC 中的日益普及，包括那些正在開髮用於治療高突變負擔實體腫瘤的 ADC，預計 DNA 損傷劑領域將在 2025 年至 2032 年間以最快的速度增長。
- 由 Linker Technology 提供
根據連接體技術，亞太地區抗體藥物偶聯物 (ADC) 市場細分為勝肽連接體、硫醚連接體、腙連接體和二硫鍵連接體。勝肽連接體細分市場在 2024 年佔據了最大的收入份額，這得益於其在腫瘤組織中的選擇性裂解以及與現代 ADC 設計的兼容性。
預測期內，硫醚連接劑部分預計將以最快的速度成長，因為它們具有化學穩定性，並且常用於 Kadcyla 等已獲批准的 ADC，支援全身循環中安全有效的藥物傳遞。
- 透過 共軛技術
根據偶聯方法，亞太地區抗體藥物偶聯物 (ADC) 市場細分為位點特異性偶聯和化學偶聯。化學偶聯在 2024 年佔據了最高的市場份額，因為它是大多數第一代和第二代 ADC 中使用的常規方法。
由於位點特異性結合部分能夠提高有效載荷輸送精度、改善治療指數並支持針對各種適應症的高級 ADC 的開發，因此預計其在預測期內將以最快的速度增長。
- 按適應症
根據適應症，亞太地區抗體藥物偶聯物 (ADC) 市場細分為乳腺癌、血癌（白血病、淋巴瘤）、肺癌、婦科癌、胃腸道癌、泌尿生殖系統癌和其他。乳癌領域佔主導地位，2024 年市佔率最大，達到 40.2%，這得益於 HER2 陽性病例的高負擔以及 Enhertu 和 Kadcyla 等已獲批准的 ADC 的廣泛使用。
由於發病率上升、非小細胞肺癌 (NSCLC) 的 ADC 臨床試驗興起以及中國和日本越來越多地採用精準醫療策略，預計肺癌領域將在 2025 年至 2032 年間經歷最快的增長率。
- 按最終用戶
根據最終用戶，亞太地區抗體藥物偶聯物 (ADC) 市場細分為醫院、專科中心、診所、門診中心、家庭醫療保健和其他。醫院在 2024 年佔據了最大的市場份額，因為它們是癌症治療和需要受控環境的 ADC 給藥的主要場所。
專科中心部門預計在預測期內將以最高的複合年增長率增長，這得益於對腫瘤學重點設施的投資不斷增加，以及患者對專門的癌症治療中心的專業化、高品質護理的需求。
- 按分銷管道
根據分銷管道，亞太地區抗體藥物偶聯物 (ADC) 市場細分為直接招標、零售銷售和其他。 2024 年，直接招標市場佔據主導地位，這主要得益於政府和私人醫院網路的集中採購，尤其是對於需要批量採購協議的昂貴腫瘤治療藥物。
由於日本和韓國等國家逐漸轉向門診癌症護理模式、擴大藥房網路以及患者透過私人醫療保健系統獲得標靶治療的機會增加，預計零售銷售部門將在預測期內以最快的速度增長。
亞太抗體藥物偶聯物（ADC）市場區域分析
- 中國在亞太抗體藥物偶聯物 (ADC) 市場佔據主導地位，2024 年其收入份額最高，為 48.1%，這得益於監管審批的加速、廣泛的臨床研究活動，以及國內公司與專注於新型 ADC 管線的全球生物技術公司之間的戰略合作夥伴關係
- 腫瘤研發投入的不斷增加、臨床試驗活動的蓬勃發展以及國內生產能力的不斷提升，進一步推動了該地區的成長。中國生物製藥產業正在迅速成熟，使其成為ADC開發和商業化的關鍵樞紐。
- 日本、韓國和澳洲等國家的優惠報銷政策、不斷增加的醫療支出以及對精準腫瘤學的認識不斷提高，也促進了區域擴張，使亞太地區成為未來幾年全球 ADC 市場的主要貢獻者
中國抗體藥物偶聯物（ADC）市場洞察
2024年，中國抗體藥物偶聯物 (ADC) 市場佔據亞太地區最大收入份額，這得益於政府扶持政策、快速增長的腫瘤藥物研發管線以及強大的國內製藥基地。 「上市許可持有人」(MAH) 制度和藥品快速審批等監管改革，使中國成為 ADC 發展的樞紐。標靶療法認知度的不斷提升，以及中國企業與全球生物技術領導企業之間的策略聯盟，進一步推動了市場擴張，尤其是在 HER2 陽性和血液系統癌症治療領域。
日本抗體藥物偶聯物（ADC）市場洞察
日本抗體藥物偶聯物 (ADC) 市場正因其先進的醫療基礎設施、對腫瘤學研發的大量投入以及創新療法的早期應用而蓬勃發展。日本成熟的製藥業和完善的報銷系統支持 ADC 等高成本生物製劑的引入。乳癌和肺癌發生率的上升，加上日本民眾對標靶治療的信任，正在推動 ADC 市場強勁成長，尤其是安全性和有效性已得到驗證的第二代和第三代 ADC。
印度抗體藥物偶聯物（ADC）市場洞察
印度抗體藥物偶聯物 (ADC) 市場預計將快速成長，這得益於癌症盛行率的上升、專科治療可及性的改善以及全球臨床試驗參與度的不斷提升。印度不斷壯大的中產階級以及對醫療基礎建設的重視，使得先進治療更加觸手可及。投資 ADC 研究的本土生物技術公司的湧現，加上「印度製造」和「2020 製藥願景」等計劃下的扶持政策，預計將顯著提升印度國內的製造和開發能力，從而提升其在亞太 ADC 市場的地位。
韓國抗體藥物偶聯物（ADC）市場洞察
由於韓國高度重視生物技術創新、政府對腫瘤學研究的資助以及生活方式相關癌症的日益增長，韓國抗體藥物偶聯物 (ADC) 市場正在穩步擴張。韓國領先的製藥公司正積極與國際生技公司合作，共同開發和商業化新的 ADC 療法。韓國精簡的監管框架和高額的醫療保健支出進一步支持將 ADC 納入各大醫院和專科癌症中心的腫瘤治療方案中。
亞太地區抗體藥物偶聯物（ADC）市場份額
亞太地區抗體藥物偶聯物（ADC）產業主要由知名公司主導，包括：
- 第一三共株式會社（日本）
- Seagen Inc.（美國）
- 阿斯特捷利康（英國）
- 榮昌生物股份有限公司 (中國)
- 邁森生物科技股份有限公司（台灣）
- 邁威(上海)生物科技有限公司 (中國)
- Mersana Therapeutics, Inc.（美國）
- Biocon Biologics Ltd.（印度）
- 藥明生物（開曼）有限公司 (中國)
- 三星生物製劑有限公司（韓國）
- 百奧泰生物科技有限公司 (中國)
- Zymeworks Inc.（加拿大）
- Prestige Biopharma 有限公司（新加坡）
- 中國抗體生物科技股份有限公司（香港）
- 協和麒麟株式會社（日本）
- 艾伯維公司（美國）
- 信達生物製藥（中國）
- 南京利茲生物科技有限公司 (中國)
- 東曜藥業股份有限公司 (中國)
- 安進公司（美國）
全球亞太抗體藥物偶聯物 (ADC) 市場的最新發展是什麼？
- 2024年4月，總部位於中國的生物製藥公司榮昌生物科技股份有限公司宣布，將其針對HER2標靶抗體偶聯藥物（ADC）disitamab vedotin的全球臨床試驗擴展至東南亞和澳洲。此舉旨在加速亞太地區監管審批，並反映了公司致力於擴大下一代癌症治療藥物可及性的策略重點。榮昌生物的這項舉措凸顯了該地區在全球腫瘤學發展中日益增長的參與度，以及其在ADC創新生態系統中日益增長的重要性。
- 2024年3月，日本第一三共株式會社與新加坡科技研究局（A*STAR）基因組研究所簽署了一項研究和許可協議，旨在探索新型ADC有效載荷和連接子技術。此次合作的重點是增強現有ADC的治療窗口，並開發針對實體腫瘤的更有針對性的療法。這項進展凸顯了亞太地區旨在推進腫瘤學研究和藥物開發的跨國合作日益增多的趨勢。
- 2024年2月，韓國三星生物製劑公司宣布進軍ADC的合約開發與生產，將自身定位為ADC生產領域的關鍵區域參與者。隨著亞太地區對外包生物製藥製造的需求不斷增長，此次擴張增強了ADC供應鏈的可擴展性，並支持區域生物技術公司以更快、更經濟的方式將新型療法推向市場。
- 2024年2月，印度Biocon Biologics公司與一家美國生技公司簽署了獨家合作協議，共同開發並商業化一系列針對婦科和胃腸道癌症的抗體偶聯藥物（ADC）。此次合作符合Biocon的戰略目標，即擴大其腫瘤產品組合，並利用印度日益完善的先進生物製劑臨床和生產基礎設施。
- 2024年1月，澳洲加文醫學研究所啟動了一項I期臨床試驗，評估與當地一家生物科技新創公司合作開發的一款針對Trop-2的新型ADC。該試驗是澳洲首批啟動的早期ADC研究之一，反映了當地研究機構在推進針對區域患者群體的標靶癌症療法方面日益重要的作用。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PESTEL ANALYSIS
5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING
5.1 ANTIBODIES
5.1.1 OVERVIEW OF ANTIBODY PRODUCTION
5.1.1.1 In-house vs. Outsourced:
5.1.2 ANTIBODY PRICING FACTORS
5.2 LINKERS
5.2.1 ROLE AND TYPES OF LINKERS
5.2.1.1 Cost Impact by Linker Type:
5.3 CYTOTOXIC AGENTS
5.3.1 COST CONSIDERATIONS:
5.3.2 BUFFERS AND SOLVENTS
5.4 COST BREAKDOWN BY MANUFACTURING STAGE
5.4.1 PRE-PRODUCTION COSTS
5.4.2 CONJUGATION PROCESS
5.4.3 PURIFICATION AND FILTRATION
5.4.4 QUALITY CONTROL
5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)
5.5.1 PROJECTED COST FLUCTUATIONS
5.5.2 COST IMPACT OF SCALABILITY
5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS
5.6.1 GEOGRAPHIC COST VARIATIONS
5.6.2 SUPPLIER ANALYSIS
5.6.3 CONCLUSION
6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY
7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES
7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES
7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES
7.3 OPPORTUNITIES
7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)
7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH
7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES
7.4 CHALLENGES
7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT
7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES
8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ENHERTU
8.3 KADCYLA
8.4 TRODELVY
8.5 POLIVY
8.6 ADCETRIS
8.7 PADCEV
8.8 BESPONSA
8.9 ELAHERE
8.1 ZYLONTA
8.11 MYLOTARG
8.12 TIVDAK
8.13 OTHERS
9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT
9.1 OVERVIEW
9.2 HER2 RECEPTOR
9.3 TROP-2
9.4 CD79B
9.5 CD30
9.6 NECTIN 4
9.7 CD22
9.8 CD19
9.9 CD33
9.1 TISSUE FACTORS
9.11 OTHERS
10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT
10.1 OVERVIEW
10.2 THIRD GENERATION ADCS
10.3 SECOND GENERATION ADCS
10.4 FOURTH GENERATION ADCS
10.5 FIRST GENERATION ADCS
11 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT
11.1 OVERVIEW
11.2 CLEAVABLE LINKERS
11.2.1 PEPTIDE BASED
11.2.2 ACID SENSITIVE OR ACID LABILE
11.2.3 GLUTATHIONE SENSITIVE DISULFIDE
11.3 NON CLEAVABLE LINKERS
12 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT
12.1 OVERVIEW
12.2 DNA DAMAGING AGENTS
12.2.1 CAMPTOTHECIN
12.2.2 CALICHEAMICIN
12.2.3 PYRROLOBENZODIAZEPINES
12.3 MICROTUBULE DISRUPTING AGENTS
12.3.1 AURISTATIN
12.3.2 MAYTANSINOIDS
13 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY
13.1 OVERVIEW
13.2 PEPTIDE LINKERS
13.3 THIOETHER LINKERS
13.4 HYDRAZONE LINKERS
13.5 DISULFIDE LINKERS
14 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY
14.1 OVERVIEW
14.2 SITE-SPECIFIC CONJUGATION
14.3 CHEMICAL CONJUGATION
15 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION
15.1 OVERVIEW
15.2 BREAST CANCER
15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)
15.4 LUNG CANCER
15.5 GYNECOLOGICAL CANCER
15.6 GASTROINTESTINAL CANCER
15.7 GENITOURINARY CANCER
15.8 OTHERS
16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CENTER
16.4 CLINICS
16.5 AMBULATORY CENTERS
16.6 HOME HEALTHCARE
16.7 OTHERS
17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
17.4 OTHERS
18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION
18.1 ASIA-PACIFIC
18.1.1 JAPAN
18.1.2 CHINA
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 SINGAPORE
18.1.6 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 DAIICHI SANKYO, INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 F. HOFFMANN-LA ROCHE LTD
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 GILEAD SCIENCES, INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 ASTELLAS PHARMA INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ABBVIE INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ADC THERAPEUTICS SA
21.7.1 6.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AMGEN, INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTRAZENECA
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 BAYER
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 BYONDIS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 EISAI INC
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 GSK PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 OXFORD BIOTHERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
21.16 PFIZER INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT UPDATES
21.17 REMEGEN
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 SANOFI
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SUTRO BIOPHARMA, INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT UPDATES
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 PROJECTED PRICE CHANGE (2024–2030)
TABLE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 4 ASIA-PACIFIC ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 ASIA-PACIFIC TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 ASIA-PACIFIC POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 ASIA-PACIFIC PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 ASIA-PACIFIC BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 ASIA-PACIFIC MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 ASIA-PACIFIC TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 17 ASIA-PACIFIC HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 ASIA-PACIFIC CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 ASIA-PACIFIC CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 28 ASIA-PACIFIC THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 ASIA-PACIFIC SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 ASIA-PACIFIC FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 ASIA-PACIFIC FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 33 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 37 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 39 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 42 ASIA-PACIFIC PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 ASIA-PACIFIC THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 ASIA-PACIFIC HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 ASIA-PACIFIC DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 47 ASIA-PACIFIC SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 ASIA-PACIFIC CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 50 ASIA-PACIFIC BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 ASIA-PACIFIC BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 52 ASIA-PACIFIC LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 ASIA-PACIFIC GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 ASIA-PACIFIC GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 ASIA-PACIFIC GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 ASIA-PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 58 ASIA-PACIFIC HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 ASIA-PACIFIC SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 60 ASIA-PACIFIC CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 ASIA-PACIFIC AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 ASIA-PACIFIC HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 63 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 64 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 66 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 67 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 70 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 72 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 73 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 74 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 75 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 76 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 77 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 78 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 79 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 80 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 81 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 82 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 84 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 87 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 88 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 89 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 90 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 91 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 92 JAPAN CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 93 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 94 JAPAN DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 95 JAPAN MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 96 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 97 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 99 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 100 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 103 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 104 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 105 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 106 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 107 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 108 CHINA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 109 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 110 CHINA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 111 CHINA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 112 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 113 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 114 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 115 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 116 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 117 CHINA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 119 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 120 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 121 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 122 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 123 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 124 INDIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 125 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 126 INDIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 127 INDIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 128 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 129 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 130 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 131 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 132 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 INDIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 134 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 135 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 136 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 137 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 138 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 139 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 140 AUSTRALIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 141 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 142 AUSTRALIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 143 AUSTRALIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 144 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 145 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 146 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 147 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 148 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 149 AUSTRALIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 152 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 153 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 154 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 155 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 156 SINGAPORE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 157 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 158 SINGAPORE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 159 SINGAPORE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 160 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 161 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 162 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 163 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 164 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SINGAPORE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 167 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 168 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
图片列表
FIGURE 1 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031
FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031
FIGURE 15 DROC
FIGURE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023
FIGURE 17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023
FIGURE 21 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)
FIGURE 22 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)
FIGURE 23 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023
FIGURE 25 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)
FIGURE 26 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)
FIGURE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023
FIGURE 29 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 30 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)
FIGURE 31 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023
FIGURE 33 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 34 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)
FIGURE 35 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023
FIGURE 37 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 38 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)
FIGURE 39 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023
FIGURE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 42 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)
FIGURE 43 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023
FIGURE 45 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 47 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023
FIGURE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 50 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 51 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 53 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 54 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 55 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)
FIGURE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
